BioArctic AB (publ) Cash Flow Conversion Efficiency
BioArctic AB (publ) cash flow conversion efficiency. Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has a cash flow conversion efficiency ratio of 0.068x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr137.84 Million ≈ $14.83 Million USD) by net assets (Skr2.02 Billion ≈ $216.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BIOA-B market cap overview for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of BioArctic AB (publ) (2015–2025)
Cash flow conversion efficiency of BioArctic AB (publ) from 2015 to 2025. This chart illustrates how BioArctic AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View BioArctic AB (publ) (BIOA-B) share price today for real-time trading data and today's change.
BioArctic AB (publ) Cash Flow Conversion Ratio Explained
BioArctic AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioArctic AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioArctic AB (publ) ranked by their cash flow conversion efficiency. Review BioArctic AB (publ) free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KWS SAAT SE & Co. KGaA
F:KWS
|
-0.054x |
|
Robotis Co.Ltd
KQ:108490
|
-0.005x |
|
Quectel Wireless Solutions Co Ltd
SHG:603236
|
0.002x |
|
Hugo Boss AG
XETRA:BOSS
|
0.076x |
|
Shanxi Securities Co Ltd
SHE:002500
|
0.284x |
|
Attica Bank S.A.
AT:TATT
|
-0.468x |
|
Bank of Xi'An Co Ltd
SHG:600928
|
0.403x |
|
Hugo Boss AG
F:BOSA
|
0.082x |
Annual Cash Flow Conversion Efficiency for BioArctic AB (publ) (2015–2025)
The table below shows the annual cash flow conversion efficiency of BioArctic AB (publ) from 2015 to 2025. Also see BIOA-B total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr1.97 Billion ≈ $211.69 Million |
Skr1.43 Billion ≈ $154.01 Million |
0.728x | +305.82% |
| 2024-12-31 | Skr894.94 Million ≈ $96.31 Million |
Skr-316.33 Million ≈ $-34.04 Million |
-0.353x | -219.45% |
| 2023-12-31 | Skr1.05 Billion ≈ $112.63 Million |
Skr309.69 Million ≈ $33.33 Million |
0.296x | +835.38% |
| 2022-12-31 | Skr786.24 Million ≈ $84.61 Million |
Skr-31.64 Million ≈ $-3.40 Million |
-0.040x | +77.41% |
| 2021-12-31 | Skr788.68 Million ≈ $84.87 Million |
Skr-140.46 Million ≈ $-15.12 Million |
-0.178x | -74.98% |
| 2020-12-31 | Skr907.30 Million ≈ $97.64 Million |
Skr-92.34 Million ≈ $-9.94 Million |
-0.102x | -130.32% |
| 2019-12-31 | Skr974.50 Million ≈ $104.87 Million |
Skr327.17 Million ≈ $35.21 Million |
0.336x | +270.79% |
| 2018-12-31 | Skr1.02 Billion ≈ $109.52 Million |
Skr-200.06 Million ≈ $-21.53 Million |
-0.197x | +7.60% |
| 2017-12-31 | Skr636.13 Million ≈ $68.46 Million |
Skr-135.33 Million ≈ $-14.56 Million |
-0.213x | -101.91% |
| 2016-12-31 | Skr60.76 Million ≈ $6.54 Million |
Skr675.13 Million ≈ $72.65 Million |
11.111x | +7421.42% |
| 2015-12-31 | Skr108.28 Million ≈ $11.65 Million |
Skr-16.43 Million ≈ $-1.77 Million |
-0.152x | -- |
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for in… Read more